Request for Covid-19 Impact Assessment of this Report
Sales, means the sales volume of Drugs for Chronic Obstructive Pulmonary Disorder
Revenue, means the sales value of Drugs for Chronic Obstructive Pulmonary Disorder
This report studies sales (consumption) of Drugs for Chronic Obstructive Pulmonary Disorder in United States market, focuses on the top players, with sales, price, revenue and market share for each player, covering
AstraZeneca
Boehringer Ingelheim
GSK
Novartis
Teva Pharmaceuticals
Ache Laboratorios Farmaceuticos
Almirall
Aquinox Pharmaceuticals
Ario Pharma
Asmacure
Astellas Pharma
BioMarck Pharmaceuticals
Others
Market Segment by States, covering
California
Texas
New York
Florida
Illinois
Split by product types, with sales, revenue, price, market share and growth rate of each type, can be divided into
Short-Acting Bronchodilators
Corticosteroids
Methylxanthines
Long-Acting Bronchodilators
Phosphodiesterase-4 Inhibitors
Split by applications, this report focuses on sales, market share and growth rate of Drugs for Chronic Obstructive Pulmonary Disorder in each application, can be divided into
GOLD 1? FEV1 ? 80%
GOLD 2? 50% ? FEV1 < 80%
GOLD 3? 30% ? FEV1 < 50%
GOLD 4? FEV1 < 30%
United States Drugs for Chronic Obstructive Pulmonary Disorder Market Report 2017
1 Drugs for Chronic Obstructive Pulmonary Disorder Overview
1.1 Product Overview and Scope of Drugs for Chronic Obstructive Pulmonary Disorder
1.2 Classification of Drugs for Chronic Obstructive Pulmonary Disorder
1.2.1 Short-Acting Bronchodilators
1.2.2 Corticosteroids
1.2.3 Methylxanthines
1.2.4 Long-Acting Bronchodilators
1.2.5 Phosphodiesterase-4 Inhibitors
1.3 Application of Drugs for Chronic Obstructive Pulmonary Disorder
1.3.1 GOLD 1? FEV1 ? 80%
1.3.2 GOLD 2? 50% ? FEV1 < 80%
1.3.3 GOLD 3? 30% ? FEV1 < 50%
1.3.4 GOLD 4? FEV1 < 30%
1.4 United States Market Size Sales (Volume) and Revenue (Value) of Drugs for Chronic Obstructive Pulmonary Disorder (2012-2022)
1.4.1 United States Drugs for Chronic Obstructive Pulmonary Disorder Sales and Growth Rate (2012-2022)
1.4.2 United States Drugs for Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2012-2022)
2 United States Drugs for Chronic Obstructive Pulmonary Disorder Competition by Manufacturers
2.1 United States Drugs for Chronic Obstructive Pulmonary Disorder Sales and Market Share of Key Manufacturers (2015 and 2016)
2.2 United States Drugs for Chronic Obstructive Pulmonary Disorder Revenue and Share by Manufactures (2015 and 2016)
2.3 United States Drugs for Chronic Obstructive Pulmonary Disorder Average Price by Manufactures (2015 and 2016)
2.4 Drugs for Chronic Obstructive Pulmonary Disorder Market Competitive Situation and Trends
2.4.1 Drugs for Chronic Obstructive Pulmonary Disorder Market Concentration Rate
2.4.2 Drugs for Chronic Obstructive Pulmonary Disorder Market Share of Top 3 and Top 5 Manufacturers
2.4.3 Mergers & Acquisitions, Expansion
3 United States Drugs for Chronic Obstructive Pulmonary Disorder Sales (Volume) and Revenue (Value) by States (2012-2017)
3.1 United States Drugs for Chronic Obstructive Pulmonary Disorder Sales and Market Share by States (2012-2017)
3.2 United States Drugs for Chronic Obstructive Pulmonary Disorder Revenue and Market Share by States (2012-2017)
3.3 United States Drugs for Chronic Obstructive Pulmonary Disorder Price by States (2012-2017)
4 United States Drugs for Chronic Obstructive Pulmonary Disorder Sales (Volume) and Revenue (Value) by Type (2012-2017)
4.1 United States Drugs for Chronic Obstructive Pulmonary Disorder Sales and Market Share by Type (2012-2017)
4.2 United States Drugs for Chronic Obstructive Pulmonary Disorder Revenue and Market Share by Type (2012-2017)
4.3 United States Drugs for Chronic Obstructive Pulmonary Disorder Price by Type (2012-2017)
4.4 United States Drugs for Chronic Obstructive Pulmonary Disorder Sales Growth Rate by Type (2012-2017)
5 United States Drugs for Chronic Obstructive Pulmonary Disorder Sales (Volume) by Application (2012-2017)
5.1 United States Drugs for Chronic Obstructive Pulmonary Disorder Sales and Market Share by Application (2012-2017)
5.2 United States Drugs for Chronic Obstructive Pulmonary Disorder Sales Growth Rate by Application (2012-2017)
5.3 Market Drivers and Opportunities
6 United States Drugs for Chronic Obstructive Pulmonary Disorder Manufacturers Profiles/Analysis
6.1 AstraZeneca
6.1.1 Company Basic Information, Manufacturing Base and Competitors
6.1.2 Drugs for Chronic Obstructive Pulmonary Disorder Product Type, Application and Specification
6.1.2.1 Short-Acting Bronchodilators
6.1.2.2 Corticosteroids
6.1.3 AstraZeneca Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)
6.1.4 Main Business/Business Overview
6.2 Boehringer Ingelheim
6.2.2 Drugs for Chronic Obstructive Pulmonary Disorder Product Type, Application and Specification
6.2.2.1 Short-Acting Bronchodilators
6.2.2.2 Corticosteroids
6.2.3 Boehringer Ingelheim Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)
6.2.4 Main Business/Business Overview
6.3 GSK
6.3.2 Drugs for Chronic Obstructive Pulmonary Disorder Product Type, Application and Specification
6.3.2.1 Short-Acting Bronchodilators
6.3.2.2 Corticosteroids
6.3.3 GSK Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)
6.3.4 Main Business/Business Overview
6.4 Novartis
6.4.2 Drugs for Chronic Obstructive Pulmonary Disorder Product Type, Application and Specification
6.4.2.1 Short-Acting Bronchodilators
6.4.2.2 Corticosteroids
6.4.3 Novartis Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)
6.4.4 Main Business/Business Overview
6.5 Teva Pharmaceuticals
6.5.2 Drugs for Chronic Obstructive Pulmonary Disorder Product Type, Application and Specification
6.5.2.1 Short-Acting Bronchodilators
6.5.2.2 Corticosteroids
6.5.3 Teva Pharmaceuticals Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)
6.5.4 Main Business/Business Overview
6.6 Ache Laboratorios Farmaceuticos
6.6.2 Drugs for Chronic Obstructive Pulmonary Disorder Product Type, Application and Specification
6.6.2.1 Short-Acting Bronchodilators
6.6.2.2 Corticosteroids
6.6.3 Ache Laboratorios Farmaceuticos Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)
6.6.4 Main Business/Business Overview
6.7 Almirall
6.7.2 Drugs for Chronic Obstructive Pulmonary Disorder Product Type, Application and Specification
6.7.2.1 Short-Acting Bronchodilators
6.7.2.2 Corticosteroids
6.7.3 Almirall Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)
6.7.4 Main Business/Business Overview
6.8 Aquinox Pharmaceuticals
6.8.2 Drugs for Chronic Obstructive Pulmonary Disorder Product Type, Application and Specification
6.8.2.1 Short-Acting Bronchodilators
6.8.2.2 Corticosteroids
6.8.3 Aquinox Pharmaceuticals Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)
6.8.4 Main Business/Business Overview
6.9 Ario Pharma
6.9.2 Drugs for Chronic Obstructive Pulmonary Disorder Product Type, Application and Specification
6.9.2.1 Short-Acting Bronchodilators
6.9.2.2 Corticosteroids
6.9.3 Ario Pharma Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)
6.9.4 Main Business/Business Overview
6.10 Asmacure
6.10.2 Drugs for Chronic Obstructive Pulmonary Disorder Product Type, Application and Specification
6.10.2.1 Short-Acting Bronchodilators
6.10.2.2 Corticosteroids
6.10.3 Asmacure Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)
6.10.4 Main Business/Business Overview
6.11 Astellas Pharma
6.12 BioMarck Pharmaceuticals
6.13 Others
7 Drugs for Chronic Obstructive Pulmonary Disorder Manufacturing Cost Analysis
7.1 Drugs for Chronic Obstructive Pulmonary Disorder Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Price Trend of Key Raw Materials
7.1.3 Key Suppliers of Raw Materials
7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.2.1 Raw Materials
7.2.2 Labor Cost
7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Drugs for Chronic Obstructive Pulmonary Disorder
8 Industrial Chain, Sourcing Strategy and Downstream Buyers
8.1 Drugs for Chronic Obstructive Pulmonary Disorder Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Drugs for Chronic Obstructive Pulmonary Disorder Major Manufacturers in 2015
8.4 Downstream Buyers
9 Marketing Strategy Analysis, Distributors/Traders
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
9.2.1 Pricing Strategy
9.2.2 Brand Strategy
9.2.3 Target Client
9.3 Distributors/Traders List
10 Market Effect Factors Analysis
10.1 Technology Progress/Risk
10.1.1 Substitutes Threat
10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change
11 United States Drugs for Chronic Obstructive Pulmonary Disorder Market Forecast (2017-2022)
11.1 United States Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue Forecast (2017-2022)
11.2 United States Drugs for Chronic Obstructive Pulmonary Disorder Sales Forecast by Type (2017-2022)
11.3 United States Drugs for Chronic Obstructive Pulmonary Disorder Sales Forecast by Application (2017-2022)
11.4 Drugs for Chronic Obstructive Pulmonary Disorder Price Forecast (2017-2022)
12 Research Findings and Conclusion
13 Appendix
Methodology
Analyst Introduction
Data Source
Figure Picture of Drugs for Chronic Obstructive Pulmonary Disorder
Table Classification of Drugs for Chronic Obstructive Pulmonary Disorder
Figure United States Sales Market Share of Drugs for Chronic Obstructive Pulmonary Disorder by Type in 2015
Figure Short-Acting Bronchodilators Picture
Figure Corticosteroids Picture
Figure Methylxanthines Picture
Figure Long-Acting Bronchodilators Picture
Figure Phosphodiesterase-4 Inhibitors Picture
Table Application of Drugs for Chronic Obstructive Pulmonary Disorder
Figure United States Sales Market Share of Drugs for Chronic Obstructive Pulmonary Disorder by Application in 2015
Figure GOLD 1? FEV1 ? 80% Examples
Figure GOLD 2? 50% ? FEV1 < 80% Examples
Figure GOLD 3? 30% ? FEV1 < 50% Examples
Figure GOLD 4? FEV1 < 30% Examples
Figure United States Drugs for Chronic Obstructive Pulmonary Disorder Sales and Growth Rate (2012-2022)
Figure United States Drugs for Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate (2012-2022)
Table United States Drugs for Chronic Obstructive Pulmonary Disorder Sales of Key Manufacturers (2015 and 2016)
Table United States Drugs for Chronic Obstructive Pulmonary Disorder Sales Share by Manufacturers (2015 and 2016)
Figure 2015 Drugs for Chronic Obstructive Pulmonary Disorder Sales Share by Manufacturers
Figure 2016 Drugs for Chronic Obstructive Pulmonary Disorder Sales Share by Manufacturers
Table United States Drugs for Chronic Obstructive Pulmonary Disorder Revenue by Manufacturers (2015 and 2016)
Table United States Drugs for Chronic Obstructive Pulmonary Disorder Revenue Share by Manufacturers (2015 and 2016)
Table 2015 United States Drugs for Chronic Obstructive Pulmonary Disorder Revenue Share by Manufacturers
Table 2016 United States Drugs for Chronic Obstructive Pulmonary Disorder Revenue Share by Manufacturers
Table United States Market Drugs for Chronic Obstructive Pulmonary Disorder Average Price of Key Manufacturers (2015 and 2016)
Figure United States Market Drugs for Chronic Obstructive Pulmonary Disorder Average Price of Key Manufacturers in 2015
Figure Drugs for Chronic Obstructive Pulmonary Disorder Market Share of Top 3 Manufacturers
Figure Drugs for Chronic Obstructive Pulmonary Disorder Market Share of Top 5 Manufacturers
Table United States Drugs for Chronic Obstructive Pulmonary Disorder Sales by States (2012-2017)
Table United States Drugs for Chronic Obstructive Pulmonary Disorder Sales Share by States (2012-2017)
Figure United States Drugs for Chronic Obstructive Pulmonary Disorder Sales Market Share by States in 2015
Table United States Drugs for Chronic Obstructive Pulmonary Disorder Revenue and Market Share by States (2012-2017)
Table United States Drugs for Chronic Obstructive Pulmonary Disorder Revenue Share by States (2012-2017)
Figure Revenue Market Share of Drugs for Chronic Obstructive Pulmonary Disorder by States (2012-2017)
Table United States Drugs for Chronic Obstructive Pulmonary Disorder Price by States (2012-2017)
Table United States Drugs for Chronic Obstructive Pulmonary Disorder Sales by Type (2012-2017)
Table United States Drugs for Chronic Obstructive Pulmonary Disorder Sales Share by Type (2012-2017)
Figure United States Drugs for Chronic Obstructive Pulmonary Disorder Sales Market Share by Type in 2015
Table United States Drugs for Chronic Obstructive Pulmonary Disorder Revenue and Market Share by Type (2012-2017)
Table United States Drugs for Chronic Obstructive Pulmonary Disorder Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Drugs for Chronic Obstructive Pulmonary Disorder by Type (2012-2017)
Table United States Drugs for Chronic Obstructive Pulmonary Disorder Price by Type (2012-2017)
Figure United States Drugs for Chronic Obstructive Pulmonary Disorder Sales Growth Rate by Type (2012-2017)
Table United States Drugs for Chronic Obstructive Pulmonary Disorder Sales by Application (2012-2017)
Table United States Drugs for Chronic Obstructive Pulmonary Disorder Sales Market Share by Application (2012-2017)
Figure United States Drugs for Chronic Obstructive Pulmonary Disorder Sales Market Share by Application in 2015
Table United States Drugs for Chronic Obstructive Pulmonary Disorder Sales Growth Rate by Application (2012-2017)
Figure United States Drugs for Chronic Obstructive Pulmonary Disorder Sales Growth Rate by Application (2012-2017)
Table AstraZeneca Basic Information List
Table AstraZeneca Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)
Figure AstraZeneca Drugs for Chronic Obstructive Pulmonary Disorder Sales Market Share (2012-2017)
Table Boehringer Ingelheim Basic Information List
Table Boehringer Ingelheim Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)
Table Boehringer Ingelheim Drugs for Chronic Obstructive Pulmonary Disorder Sales Market Share (2012-2017)
Table GSK Basic Information List
Table GSK Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)
Table GSK Drugs for Chronic Obstructive Pulmonary Disorder Sales Market Share (2012-2017)
Table Novartis Basic Information List
Table Novartis Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)
Table Novartis Drugs for Chronic Obstructive Pulmonary Disorder Sales Market Share (2012-2017)
Table Teva Pharmaceuticals Basic Information List
Table Teva Pharmaceuticals Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)
Table Teva Pharmaceuticals Drugs for Chronic Obstructive Pulmonary Disorder Sales Market Share (2012-2017)
Table Ache Laboratorios Farmaceuticos Basic Information List
Table Ache Laboratorios Farmaceuticos Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)
Table Ache Laboratorios Farmaceuticos Drugs for Chronic Obstructive Pulmonary Disorder Sales Market Share (2012-2017)
Table Almirall Basic Information List
Table Almirall Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)
Table Almirall Drugs for Chronic Obstructive Pulmonary Disorder Sales Market Share (2012-2017)
Table Aquinox Pharmaceuticals Basic Information List
Table Aquinox Pharmaceuticals Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)
Table Aquinox Pharmaceuticals Drugs for Chronic Obstructive Pulmonary Disorder Sales Market Share (2012-2017)
Table Ario Pharma Basic Information List
Table Ario Pharma Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)
Table Ario Pharma Drugs for Chronic Obstructive Pulmonary Disorder Sales Market Share (2012-2017)
Table Asmacure Basic Information List
Table Asmacure Drugs for Chronic Obstructive Pulmonary Disorder Sales, Revenue, Price and Gross Margin (2012-2017)
Table Asmacure Drugs for Chronic Obstructive Pulmonary Disorder Sales Market Share (2012-2017)
Table Astellas Pharma Basic Information List
Table BioMarck Pharmaceuticals Basic Information List
Table Others Basic Information List
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Drugs for Chronic Obstructive Pulmonary Disorder
Figure Manufacturing Process Analysis of Drugs for Chronic Obstructive Pulmonary Disorder
Figure Drugs for Chronic Obstructive Pulmonary Disorder Industrial Chain Analysis
Table Raw Materials Sources of Drugs for Chronic Obstructive Pulmonary Disorder Major Manufacturers in 2015
Table Major Buyers of Drugs for Chronic Obstructive Pulmonary Disorder
Table Distributors/Traders List
Figure United States Drugs for Chronic Obstructive Pulmonary Disorder Production and Growth Rate Forecast (2017-2022)
Figure United States Drugs for Chronic Obstructive Pulmonary Disorder Revenue and Growth Rate Forecast (2017-2022)
Table United States Drugs for Chronic Obstructive Pulmonary Disorder Production Forecast by Type (2017-2022)
Table United States Drugs for Chronic Obstructive Pulmonary Disorder Consumption Forecast by Application (2017-2022)
Table United States Drugs for Chronic Obstructive Pulmonary Disorder Sales Forecast by States (2017-2022)
Table United States Drugs for Chronic Obstructive Pulmonary Disorder Sales Share Forecast by States (2017-2022)
Proteins that are designed and engineered in the laboratory for pharmaceutical interventions to treat different diseases are known as protein therapeutics. The global protein therapeutics market accounted for $140,109 million in 2016, and is anticipated to rea...
Umbilical cord blood bank is storage facility that collects cord blood after the childbirth from placenta. Cord blood is rich source of stem cell used in treatment of different chronic diseases. Private and public cord blood banks are the two major types of banks that are prevalent in th...
The pharmaceutical agents that are administered to treat, diagnose, and prevent life-threatening diseases (rare diseases) are known as orphan drugs. The global orphan drugs market accounted for $106 billion in 2015, and is anticipated to reach $169 billio...